CALGARY, March 29, 2012 /PRNewswire/ – Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC) (NASDAQ:ONCY) announced today that abstracts of preclinical research on reovirus (REOLYSIN®) are available on the American Association for Cancer Research (AACR) website at www.aacr.org. The research is scheduled to be presented at the 2012 AACR Annual Meeting in Chicago, IL, which takes place from March 31 to April 4, 2012.“We are delighted to see that the research community has been embracing preclinical research utilizing [...]

Both Tyrosine Kinase Inhibitors Overcome Drug Resistance Due to “Gatekeeper” Mutations Of Multiple Oncogenic TargetsCAMBRIDGE, Mass. & CHICAGO–(BUSINESS WIRE)–Apr 2, 2012 – ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentation of new preclinical data on its investigational pan-BCR-ABL inhibitor, ponatinib, and its investigational dual EGFR-ALK inhibitor, AP26113, at the American Association for Cancer Research Annual Meeting in Chicago. Both drug candidates, discovered using ARIAD’s structure-based drug design platform, are potent inhibitors of multiple “gatekeeper” [...]

Brodalumab Moving Into Phase 3 for Moderate to Severe PsoriasisTHOUSAND OAKS, Calif., March 28, 2012 /PRNewswire/ — Amgen (NASDAQ: AMGN) announced today that results from a Phase 2 trial evaluating the safety and efficacy of brodalumab (formerly AMG 827) in 198 patients with moderate to severe plaque psoriasis were published in the New England Journal of Medicine. The 12-week, dose-ranging study achieved its primary endpoint with the mean percentage improvement in psoriasis area and severity [...]

Data From Phase I Trial Evaluating Bavituximab Plus Carboplatin and Pemetrexed Indicate Encouraging Anti-Tumor Activity and a Positive Safety Profile; Data From Imaging Studies Show Potent Upregulation of Bavituximab’s PS Target Following Docetaxel Treatment Further Supporting Ongoing Bavituximab Plus Docetaxel Phase II NSCLC TrialTUSTIN, CA — (Marketwire) — 04/02/12 — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today highlighted data(1) presented [...]

Data Presented at the American Association for Cancer Research 2012 Annual MeetingCHICAGO and AUSTIN, Texas, April 2, 2012 /PRNewswire/ — Genprex, Inc. — New data demonstrating the anti-cancer activities of Oncoprex® were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, IL.  The study, “Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1 nanoparticles in LKB1 mutant NSCLC” (Meng J, Lara-Guerra H, Ji L, Roth JA) is authored [...]

WOBURN, Mass.–(BUSINESS WIRE)–Mar 29, 2012 – ArQule, Inc. (Nasdaq: ARQL) today announced eight presentations of clinical and pre-clinical data for tivantinib (ARQ 197) at the Annual Meeting of the American Association for Cancer Research (AACR), held from March 31 – April 4 in Chicago, Illinois. Tivantinib is an oral inhibitor of c-MET, a receptor tyrosine kinase, which is currently in Phase 3 clinical trials for non-squamous non-small cell lung cancer (NSCLC). Several other studies related [...]

Preliminary results from clinical trials in a subtype of lymphoma show that for a number of patients whose disease was not cured by other treatments, the drug ibrutinib can provide significant anti-cancer responses with modest side effects. These results were presented as part of the opening plenary session at the American Association of Cancer Research (AACR) Annual Meeting 2012 on April 1 by researchers at the National Cancer Institute (NCI), part of the National Institutes [...]

- Data Highlight Enhanced Potency and Favorable Pharmacokinetics of New Agents Against Pseudomonas and Gram-Negative Respiratory Pathogens -WATERTOWN, Mass.–(BUSINESS WIRE)–Apr 2, 2012 – Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results from studies that demonstrate the improved potency and pharmacokinetics of several of its newest discovery-stage tetracycline analogs. These data, which focus on significant gram-negative pathogens – including Pseudomonas aeruginosa, and troublesome gram-positive respiratory [...]

PHILADELPHIA, Pennsylvania, March 30, 2012/PRNewswire-FirstCall/ –Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX(R) mesalamine in patients with a history of diverticulitis.[1] The study, conducted in 10 countries worldwide including the United States, did not meet the primary endpoint in reducing the rate of recurrence of diverticulitis over a 2-year treatment period. In addition, SPD476, MMX [...]